MAPK
As MAPKs são uma família de proteínas quinases envolvidas em uma variedade de processos celulares, incluindo crescimento, proliferação, diferenciação e respostas ao estresse. A via de sinalização MAPK consiste em várias camadas, incluindo ERK, JNK e p38 MAPKs, cada uma desempenhando papéis distintos na função celular. A desregulação da sinalização MAPK está ligada ao câncer, doenças inflamatórias e distúrbios metabólicos. Na CymitQuimica, oferecemos uma ampla gama de inibidores e ativadores de MAPK para apoiar sua pesquisa em biologia celular, transdução de sinais e mecanismos de doenças.
Foram encontrados 885 produtos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Mitogen-activated protein kinase 1
CAS:<p>Mitogen-activated protein kinase 1 (MAPK1) activates the p38/NF-κB pathway and regulates cellular processes in sepsis-associated diseases.</p>Pureza:98%Cor e Forma:SolidJNK-IN-18
JNK-IN-18 (compound 23b) is a potent inhibitor of JNK1, boasting an IC50 of 2 nM. It demonstrates superior efficacy when compared to its IC50 values of 125 nM for JNK2 and 98 nM for BRAF(V600E).Cor e Forma:Odour SolidKRAS mutant protein inhibitor 1
CAS:<p>KRAS mutant protein inhibitor 1 is a KRAS mutant protein inhibitor for potential treatment in cancer.</p>Fórmula:C31H27Cl3FN7O2Cor e Forma:SolidPeso molecular:654.95Ras Inhibitory Peptide
CAS:<p>Sos1, a GEF, activates ERK by converting Ras-GDP to Ras-GTP via Grb2. The PVPPR peptide inhibits this by blocking Sos1/Grb2 binding.</p>Fórmula:C53H91N19O11Cor e Forma:SolidPeso molecular:1170.433Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Cor e Forma:Odour SolidSIAIS562055
<p>SIAIS562055, a potent cereblon-based SOS1PROTAC, exhibits a dissociation constant (Kd) of 95.9 nM. It effectively degrades SOS1 and inhibits the downstream ERK pathway. SIAIS562055 disrupts the interaction between KRASG12C or KRASG12D and SOS1, with IC50 values of 95.7 nM and 134.5 nM, respectively. This compound demonstrates strong anticancer activity.</p>Fórmula:C49H62F3N7O5SCor e Forma:SolidPeso molecular:918.12Tagarafdeg
CAS:<p>Tagarafdeg (CFT1946) is a PROTAC degradator targeting mutant BRAF, capable of degrading BRAF V600E, G469A, G466V mutations, anti proliferation.</p>Fórmula:C45H49F2N11O9SPureza:＞99.99%Cor e Forma:SolidPeso molecular:958Ras Inhibitory Peptide acetate
<p>Ras Inhibitory Peptide acetate, involved in cancer-related Ras signaling.</p>Fórmula:C55H95N19O13Pureza:96.63%Cor e Forma:SolidPeso molecular:1230.46PROTAC SOS1 degrader-2
CAS:<p>PROTAC SOS1 degrader-2 reduces pERK & RAS-GTP, inhibiting tumor growth dose-dependently in vivo.</p>Fórmula:C57H76ClFN10O4SCor e Forma:SolidPeso molecular:1051.79RTIL 13
CAS:<p>RTIL 13 inhibits dynamin GTPase (IC50: 2.3 μM), targets its lipid binding domain, and suppresses endocytosis (IC50: 9.3 & 7.1 μM).</p>Fórmula:C30H55BrN2O3Cor e Forma:SolidPeso molecular:571.685PROTAC SOS1 degrader-4
<p>PROTAC SOS1 Degrader-4 (compound 10) is a potent degrader of SOS1 and exhibits antiproliferative activity [1].</p>Fórmula:C53H65ClN8O7SPureza:98%Cor e Forma:SolidPeso molecular:993.65PPM-3
<p>PPM-3, a selective PROTAC ERK5 degrader, exhibits a potent inhibitory concentration (IC 50) of 62.4 nM.</p>Fórmula:C54H69N11O6SPureza:98%Cor e Forma:SolidPeso molecular:1000.26Rineterkib hydrochloride
CAS:<p>Rineterkib hydrochloride (B) is an oral RAF/ERK1/2 inhibitor for MAPK-driven cancers, including KRAS/BRAF-mutant NSCLC and CRC.</p>Fórmula:C26H28BrClF3N5O2Cor e Forma:SolidPeso molecular:614.89Pan-RAS-IN-7
CAS:Pan-RAS-IN-7 (Compound D101) is a broad-spectrum RAS inhibitor used in the synthesis of antibody-drug conjugates (ADCs). It is also applicable in cancer research.Fórmula:C59H76N8O8Cor e Forma:SolidPeso molecular:1025.28R18
CAS:<p>14.3.3 protein antagonist, blocks binding to Raf-1/Bad/ASK1/exoenzyme S, competitive, no phosphorylation needed, KD ~80 nM.</p>Fórmula:C101H157N27O29S3Pureza:98%Cor e Forma:SolidPeso molecular:2309.69KRAS G12D inhibitor 7
CAS:<p>KRAS G12D inhibitor 7, is a highly potent inhibitor specifically targeting KRAS G12D.</p>Fórmula:C32H38N8O3Cor e Forma:SolidPeso molecular:582.709Pan-RAS-IN-6
Pan-RAS-IN-6 (compound 24) serves as a DUSP6 inhibitor, effectively reducing MAPK activation in the NCI-H1373-Luc model (DUSP6). It concurrently exhibits notable tumor growth inhibition and regression in the NSCLC brain metastasis mouse model. The compound displays high selectivity and potent inhibitory effects, particularly on KRAS mutation-associated signaling pathways. It demonstrates varied inhibitory activities against distinct KRAS mutants and their interacting proteins. The IC 50 values for KRAS G12C, G12D, and G12V are 1.3 nM, 4.7 nM, and 0.3 nM, respectively.Fórmula:C46H60N8O5SCor e Forma:SolidPeso molecular:837.08Cyclotraxin B
CAS:<p>TrkB receptor antagonist; inhibits BDNF-TrkB signaling (IC50 = 0.30 nM); alters receptor shape; may reduce anxiety in mice.</p>Fórmula:C48H73N13O17S3Pureza:98%Cor e Forma:SolidPeso molecular:1200.36BTX6654
<p>BTX-6654 is a cereblon-based bifunctional SOS1 PROTAC degrader. This compound exhibits antiproliferative activity against cells with various KRAS mutations by reducing the expression of downstream signaling markers pERK and pS6.</p>Fórmula:C50H57F4N9O5Cor e Forma:SolidPeso molecular:940.04PROTAC K-Ras Degrader-3
CAS:<p>PROTAC K-Ras Degrader-3 is a PROTAC degrader targeting K-Ras, exhibiting a DC50 value of ≤ 1 nM against SW620 KRAS G12D and a GI50 value of ≤ 10 nM in inhibiting the growth of SW620 3D cells. It is used in cancer research.</p>Fórmula:C57H67F2N9O6Cor e Forma:SolidPeso molecular:1012.20
